235 related articles for article (PubMed ID: 38175465)
1. Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease.
Stumpf J; Al-Sawaf O
Curr Oncol Rep; 2024 Feb; 26(2):136-146. PubMed ID: 38175465
[TBL] [Abstract][Full Text] [Related]
2. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
3. Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.
Wierda WG; Kipps TJ; Al-Sawaf O; Chyla B; Biondo JML; Mun Y; Jiang Y; Seymour JF
Leuk Lymphoma; 2022 Dec; 63(12):2765-2784. PubMed ID: 35983732
[TBL] [Abstract][Full Text] [Related]
4. Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic Leukemia.
Al-Sawaf O
Acta Haematol; 2024; 147(1):22-32. PubMed ID: 37903476
[TBL] [Abstract][Full Text] [Related]
5. Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
Thompson M; Brander D; Nabhan C; Mato A
JAMA Oncol; 2018 Mar; 4(3):394-400. PubMed ID: 28750119
[TBL] [Abstract][Full Text] [Related]
6. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
7. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Suzumiya J; Takizawa J
Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666
[TBL] [Abstract][Full Text] [Related]
8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
9. Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
Van Den Neste E; Letestu R; Aurran-Schleinitz T; Ysebaert L; Feugier P; Leprêtre S; Dartigeas C
Leuk Lymphoma; 2012 Mar; 53(3):362-70. PubMed ID: 21854093
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease in chronic lymphocytic leukaemia.
García Vela JA; García Marco JA
Med Clin (Barc); 2018 Feb; 150(4):144-149. PubMed ID: 28864095
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.
Eyre TA; Hori S; Munir T
Hematol Oncol; 2022 Apr; 40(2):129-159. PubMed ID: 34713475
[TBL] [Abstract][Full Text] [Related]
12. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
Thompson PA; Wierda WG
Blood; 2016 Jan; 127(3):279-86. PubMed ID: 26576865
[TBL] [Abstract][Full Text] [Related]
13. MRD-directed therapy in CLL: ready for prime time?
Rhodes JM; Lopez CA; Barrientos JC
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):413-420. PubMed ID: 38066928
[TBL] [Abstract][Full Text] [Related]
14. Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis.
Molica S; Giannarelli D; Montserrat E
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):423-430. PubMed ID: 31027992
[TBL] [Abstract][Full Text] [Related]
15. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice.
Rios-Olais FA; Hilal T
Curr Treat Options Oncol; 2023 Aug; 24(8):907-928. PubMed ID: 37195588
[TBL] [Abstract][Full Text] [Related]
16. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Odetola O; Ma S
Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
[TBL] [Abstract][Full Text] [Related]
17. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ
J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Shadman M
JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
[TBL] [Abstract][Full Text] [Related]
19. Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia.
Lipsky AH; Lamanna N
Cancer; 2023 Jan; 129(1):18-31. PubMed ID: 36326285
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
